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A B S T R A C T
Pseudomonas aeruginosa chronic infections are the major cause of high morbidity and mortality in cystic ﬁbrosis
(CF) patients due to the use of sophisticated mechanisms of adaptation, including clonal diversiﬁcation into
specialized CF-adapted phenotypes. In contrast to chronic infections, very little is known about what occurs after
CF lungs colonization and at early infection stages.
This study aims to investigate the early events of P. aeruginosa adaptation to CF environment, in particular, to
inspect the occurrence of clonal diversiﬁcation at early stages of infection development and its impact on an-
tibiotherapy eﬀectiveness.
To mimic CF early infections, three P. aeruginosa strains were long-term grown in artiﬁcial sputum (ASM) over
10 days and phenotypic diversity veriﬁed through colony morphology characterization. Bioﬁlm sub- and in-
hibitory concentrations of ciproﬂoxacin were applied to non- and diversiﬁed populations to evaluate antibiotic
eﬀectiveness on P. aeruginosa eradication.
Our results demonstrated that clonal diversiﬁcation might occur after ASM colonization and growth.
However, this phenotypic diversiﬁcation did not compromise ciproﬂoxacin eﬃcacy in P. aeruginosa eradication
since a bioﬁlm minimal inhibitory dosage would be applied. The expected absence of mutators in P. aeruginosa
populations led us to speculate that clonal diversiﬁcation in the absence of ciproﬂoxacin treatments could be
driven by niche specialization. Yet, bioﬁlm sub-inhibitory concentrations of ciproﬂoxacin seemed to overlap
niche specialization as “ﬁtter” variants emerged, such as mucoid, small colony and pinpoint variants, known to
be highly resistant to antibiotics. The pathogenic potential of all emergent colony morphotypes-associated
bacteria, distinct from the wild-morphotypes, revealed that P. aeruginosa evolved to a non-swimming phenotype.
Impaired swimming motility seemed to be one of the ﬁrst evolutionary steps of P. aeruginosa in CF lungs that
could pave the way for further adaptation steps including bioﬁlm formation and progress to chronic infection.
Based on our ﬁndings, impaired swimming motility seemed to be a candidate to disease marker of P. aeruginosa
infection development. Despite our in vitro CF model represents a step forward towards in vivo scenario simu-
lation and provided valuable insights about the early events, more and distinct P. aeruginosa strains should be
studied to strengthen our results.
1. Introduction
Cystic ﬁbrosis (CF) is an autosomal recessive disease caused by a
defect in the cystic ﬁbrosis conductance regulator gene resulting in
several complications in the human body (Kreda et al., 2012). So far,
the pathological changes in the lungs are the best studied due to the
high mortality rates linked to the poor lung function and the recurrent
development of microbial infections (Flume et al., 2009; Ciofu et al.,
2014). CF lungs are often colonized or infected with a complex mi-
crobial ﬂora, mainly composed by bacteria, provoking acute and
chronic infections (Bittar et al., 2008; Coburn et al., 2015). Pseudo-
monas aeruginosa is the most common pathogen isolated from CF
sputum and its presence is highly associated with increased exacerba-
tions, decline of the lung function and patients death (Bittar et al.,
2008; Coutinho et al., 2008; Folkesson et al., 2012).
In attempt to eradicate P. aeruginosa infections, numerous antibiotic
strategies have been used varying in the route of drug administration
(systemic, oral, inhaled antibiotics or route combination), classes of
antibiotics and treatment duration (Schelstraete et al., 2013; Langan
et al., 2015). Despite these advances and the long and aggressive
https://doi.org/10.1016/j.ijmm.2018.10.003
Received 4 June 2018; Received in revised form 16 September 2018; Accepted 10 October 2018
⁎ Corresponding author at: Centre of Biological Engineering, University of Minho, 4710–057, Braga, Portugal.
E-mail address: mopereira@deb.uminho.pt (M.O. Pereira).
International Journal of Medical Microbiology 308 (2018) 1053–1064
1438-4221/ © 2018 Elsevier GmbH. All rights reserved.
T
antibiotic treatments, P. aeruginosa is still able to persist causing chronic
infections almost impossible to eradicate (Mayer-Hamblett et al., 2012).
This long-term persistence of P. aeruginosa in CF lungs has been asso-
ciated with its clonal diversiﬁcation, or expansion, into specialized
phenotypes. During infection progression in CF lungs, P. aeruginosa
switches from an acute environmental virulent pathogen, characteristic
of early infection stages, to a CF-adapted pathogen, typical of chronic
infection stages (Sousa and Pereira, 2014). The microbiological analysis
of chronic isolates revealed changes in several P. aeruginosa phenotypic
traits such as colony morphology with distinct consistency, size, texture
and colour, inactivation of quorum sensing, hypermutability, loss of O-
antigen components of the lipopolysaccharide, loss of motility, re-
sistance to antibiotics, changes in nutritional requirements and other
virulence-associated traits (Bragonzi et al., 2009; Rau et al., 2010;
Workentine et al., 2013; Jiricny et al., 2014). In fact, some of these
factors have been considered the hallmark of CF disease and can even
be indicative of the chronic infection stage, such as the alteration of
colony morphology to the mucoid phenotype and to small colony var-
iants (SCV).
Mucoid colony morphology results from alginate overproduction,
absence of ﬂagellin and pilin and expression of other virulence factors
(Hogardt and Heesemann, 2010). Within the mucoid form, P. aeruginosa
is more diﬃcult to eradicate because alginate promotes its encapsula-
tion and bioﬁlm formation, protecting bacteria from the action of re-
active oxygen species, antibiotics and host immune defences, and as-
sisting its persistence in CF lungs (Qiu et al., 2007; Hassett et al., 2009;
Høiby et al., 2010).
P. aeruginosa SCV, the small-sized colonies typically with 1–3mm of
diameter after 24–48 h of growth, are also frequently isolated from
chronic CF lung infections, mainly after long antibiotic courses
(Haussler et al., 1999; Kahl, 2014). These colony variants are normally
hyperpiliated, hyperadherent, excellent bioﬁlm formers and exhibit
autoaggregative behavior and increased twitching motility (Deziel
et al., 2001; Haussler et al., 2003; Haussler, 2004; Kirisits et al., 2005).
Moreover, SCV display augmented resistance to several classes of an-
tibiotics, notably to aminoglycosides, contributing to P. aeruginosa
persistence in CF airways and decline of lung function (Haussler et al.,
1999; Kahl, 2014). Other colony morphologies have also been isolated
from CF airways but their roles in P. aeruginosa persistence and in in-
fection progression in CF lungs remain unclear so far (Rakhimova et al.,
2008; Workentine et al., 2013; Clark et al., 2015).
When P. aeruginosa is identiﬁed, the gold standard of CF disease
management is its eradication from CF lungs as soon as detected (Ratjen
et al., 2010; Emiralioglu et al., 2016; Ratjen et al., 2018). Early eradi-
cation of P. aeruginosa is of upmost importance as it avoids or, at least,
retards the development of chronic infections preserving lung function.
However, some antibiotics fail in early eradication of P. aeruginosa
giving rise to serious complications, as the emergence of resistant
subpopulations, which can pave the way for the establishment of a
chronic infection (Ratjen, 2006; Mayer-Hamblett et al., 2014a,b).
Therefore, early antibiotic treatment must be adequately designed in
order to obtain successful P. aeruginosa eradication. However, very little
is known about the early adaptations that P. aeruginosa underwent after
CF lungs colonization and which impact they have on the eﬀectiveness
of the ﬁrst antibiotic treatments. Without understanding the early
events of P. aeruginosa adaptation to CF lungs, improving antimicrobial
stewardships could be a goal hard to achieve. In the light of this
knowledge gap, this study put special emphasis on the monitoring of
initial P. aeruginosa colonization and early growth within CF artiﬁcial
sputum using a novel in vitro CF model. The main goal of this study was
to understand the early adaptation mechanisms that P. aeruginosa uses
to adapt and grow in CF environment and also to evade the action of
antimicrobial agents, events up to now unclear. In particular, this study
intends to inspect the occurrence of clonal diversiﬁcation, after simu-
lated CF lungs colonization by P. aeruginosa, to gain insights into the
driving forces that can trigger diversiﬁcation and, also, to determine the
impact of clonal diversiﬁcation in antibiotic eﬀectiveness.
2. Materials & methods
2.1. Bacterial strains and culture conditions
P. aeruginosa PAO1, ATCC® 39324 and a clinical isolated PAI were
used throughout this study. The rationale behind the selection of the
strains was based on the source and routes of P. aeruginosa transmission
to CF patients. Most of the CF patients are colonized by environmental
strains (Burns et al., 2001; Speert et al., 2002), but also via contact with
other non- and CF patients (UK Cystic Fibrosis Trust, 2004). PAO1 is a
non-mucoid laboratory strain that never contacted with CF environ-
ment (Stover et al., 2000). PAI is a respiratory clinical isolate non-CF
related kindly provided by the Hospital of Braga (Braga, Portugal)
(Pires et al., 2011). P. aeruginosa ATCC® 39324, from now on referred as
ATCC, is a CF strain able to produce an exo-polysaccharide conferring
mucoidy appearance (data obtained from ATCC® product sheet). Bac-
teria were routinely cultured on Trypic Soy Broth (TSB, Lioﬁlchem) or
Trypic Soy Agar (TSA, Lioﬁlchem) at 37 °C. All strains were preserved
in criovials (Nalgene) at – 80 ± 2 °C to minimise putative adaptation to
the laboratory environment. Prior to each experiment, bacterial cells
were grown on TSA plates overnight at 37 °C.
2.2. P. aeruginosa bioﬁlm-cells susceptibility to ciproﬂoxacin
Bioﬁlms were developed as previously described (Stepanovic et al.,
2000). Brieﬂy, overnight cultures of each strain, grown in TSB at 37 °C
and 120 rpm in air conditions, were washed in sterile water and diluted
in TSB to obtain 1×107 CFU/mL as ﬁnal concentration. Triplicate
wells of a 96-well polystyrene microtiter plate (Orange Scientiﬁc) were
inoculated with 200 μL of the bacterial suspensions to form bioﬁlms for
24 h at 37 °C on a horizontal shaker (120 rpm). After that, the liquid
content was withdrawn and bioﬁlms washed twice with sterile water to
remove weakly adhered cells. Plates were then ﬁlled with sterile water
and placed on an ultrasound bath (Sonic model SC-52, UK) for 6min
(time previously optimized by Magalhães et al. (2016)) to detach bio-
ﬁlm-cells. Then, bioﬁlm-cells suspensions were gently vortexed to
homogenize and used to assess the susceptibility of the bioﬁlm-derived
cells towards ciproﬂoxacin (Fluka), testing a range of concentrations
from 0,125 to 16mg/L.
The ciproﬂoxacin susceptibility proﬁles of the bioﬁlm-cells were
established determining the minimum inhibitory concentration (MIC)
by microdilution broth assay following the recommendations of the
CLSI (Clinical and Laboratory Standards Institute, 2007). Brieﬂy, sterile
96-well round-bottom microtiter plates (polystyrene, Orange, USA)
were ﬁlled in with 100 μL of Muller-Hinton Broth (Lioﬁlchem) with
increasing concentrations of ciproﬂoxacin and further 100 μL of each
bioﬁlm-cell suspension were added at a ﬁnal concentration of 5× 105
CFU/mL. The plates were afterwards incubated at 37 °C for 18–21 h in
an orbital shaker at 120 rpm. In this assay, two controls were used, one
without bacteria, as a negative control and one without ciproﬂoxacin,
as a positive control. The MIC was obtained by measuring the absor-
bance at 640 nm (A640nm), where clear wells (A640nm = negative con-
trol) were evidence of bacterial growth inhibition.
2.3. In vitro growth of P. aeruginosa in an artiﬁcial CF lung environment
2.3.1. Artiﬁcial sputum medium preparation
Artiﬁcial sputum medium (ASM) was used to mimic the sputum of
CF patients and it was prepared as described by Sriramulu et al. (2005).
Brieﬂy, 5 g/L of mucin from pig stomach (Sigma-Aldrich), 4 g/L of DNA
from salmon sperm (Sigma-Aldrich), 5.9 mg/L of diethylene triamine
pentaacetic acid (DTPA, Sigma-Aldrich), 5 g/L of NaCl, 2.2 g/L of KCl
and 5 g/L of casoamino acids (AMESRO) were resuspended in water
and the pH adjusted to 7 with Tris base. This ASM was then sterilized in
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an autoclave at 110 °C for 15min and, after cooled, 5mL of egg yolk
emulsion (Fluka) were added.
2.4. Long-term in vitro maintenance model of P. aeruginosa in ASM
Overnight P. aeruginosa inocula of each bacterial strain were washed
twice in sterile water by centrifugation (9000g, 5 min) and further serial
diluted in sterile water to a ﬁnal concentration of 4× 109 CFU/mL.
Two mL of ASM were transferred to each well of a 24 well-plate
(polystyrene, Orange, USA) and inoculated on the top with 5 μL of the
bacterial cell suspensions, obtaining a ﬁnal cellular concentration in
each well of 1×107 CFU/mL. ASM cultures were incubated at 37 °C
aerobically for 10 days, to mimic the early stage of CF lung disease, and
in static culture conditions to resemble the reduced or absent cilia
movements in CF lungs (Worlitzsch et al., 2002; Hassett et al., 2009).
After 1, 3, 5, 7 and 10 days of bacterial growth in ASM, the content of
the wells was collected aseptically and vigorously shaken to detach cells
from the small aggregates or cells adhered to mucin. These experiments
were performed at least 5 times. The resulting cell suspensions of each
sampling time were analysed in terms of cell viability and phenotypic
diversiﬁcation.
2.5. Application of ciproﬂoxacin treatments to ASM-grown populations
To investigate the impact of early phenotypic diversiﬁcation in the
eﬀectiveness of antibiotic treatment, two strategies of ciproﬂoxacin
application were followed. First, ciproﬂoxacin was applied to non-di-
versiﬁed P. aeruginosa populations, being thus added to the top of ASM
cultures 30min after bacterial inoculation and every 24 h over 10 days.
The second therapeutic strategy was applied against phenotypic di-
versiﬁed populations adding ciproﬂoxacin to ASM cultures after 5 days
of bacterial growth (when diversiﬁcation was observed) and every 24 h
over the last 5 days. For each strategy, two diﬀerent concentrations
were used, a sub- and a bioﬁlm inhibitory concentration, according to
the MIC outcomes determined for bioﬁlm-cells of each of the three
strains. For both strategies, ASM-grown populations were studied as
above described. All experiments were performed at least 5 times.
2.6. Cell viability determination
The viability of the bacterial cells was determined through colony-
forming unit (CFU). For CFU counts, both non- and treated cell sus-
pensions were serial diluted, plated on TSA and incubated overnight at
37 °C. After that, the number of colonies was counted and veriﬁed after
more 24 h of growth to ensure that slow growing bacteria were reck-
oned. These CFU counts were used to plot the growth kinetics of the P.
aeruginosa strains grown in ASM and the time killing curves for cipro-
ﬂoxacin.
2.7. Phenotypic diversiﬁcation during bacterial growth in ASM
The occurrence of P. aeruginosa clonal diversiﬁcation was assessed
through colony morphology inspection over time. P. aeruginosa popu-
lations grown in ASM were allowed to grow on TSA plates during 48 h
at 37 °C in air conditions as previously optimized by Sousa et al. (2013),
ensuring thus that the conditions used to observe phenotypic diversity
were fully controlled and identical in all over the experiments. Colony
morphologies were observed by directly placing the Petri plates on a
magnifying glass (Olympus SZ-CTV) and photographed in a CCD
camera (AVC, D5CE; Sony, Tokio, Japan). The morphological features
of the colonies were annotated using the morphological criteria pre-
viously stipulated (Sousa et al., 2015). In brief, P. aeruginosa colonies
were evaluated according to their form, margin, type of surface, tex-
ture, size, sheath, elevation, opacity, consistency and colour. Wild-
colony morphotype (WMT) of each P. aeruginosa strain was established
studying inoculum cultures plated in the same abovementioned
conditions. The distinct colony morphotypes (MT) identiﬁed were re-
ferenced with an identity number, for instance MT01. The identity
numbers had not any correlation with the order of emergence or re-
lationships with other colony morphotypes within populations, being
used only to refer colonies with common features and distinguish them
from each other. The estimated relative abundance of each colony
morphotype was calculated based on the proportion of a morphotype in
our photographically records of the population.
The diﬀerent morphotype-forming bacteria were characterized ac-
cording to the virulence determinants more relevant in the CF context,
namely bioﬁlm formation, motility, auxotrophy, pigments and hemo-
lysin production and their antibiotic susceptibility.
2.8. Pathogenic potential of the diﬀerent colony morphotype-forming
bacteria
2.8.1. Bioﬁlm formation
The ability of colony morphotype-associated bacteria to form bio-
ﬁlms was assessed by the crystal violet (CV) method (Peeters et al.,
2007). Colony morphotypes were suspended and diluted in TSB to
obtain a ﬁnal concentration of 1×107 CFU/mL. This cell suspension
was transferred to 96-well microtitre plates (200 μL per well) being then
incubated at 37 °C for 24 h under agitation (120 rpm) in air conditions.
After 24 h of bioﬁlm formation, the liquid content of the plates was
discarded and the adhered biomass washed twice with sterile water in
order to remove weakly attached cells. Afterwards, 200 μL per well of
methanol were added and plates were allowed to stand for 15min in
order to ﬁx the bioﬁlm-mass. Methanol was discarded and plates were
left to dry at room temperature. Bioﬁlms were stained with 200 μL of
pure CV for approximately 5min and then rinsed thoroughly and re-
peatedly with tap water. Finally, the amount of bioﬁlm was quantiﬁed
by solubilization of the CV in 200 μL of 33% (v/v) acetic acid. The
absorbance was measured at 570 nm using a microtiter plate reader
(Bio-Rek Synergy HT, Izasa).
2.8.2. Motility
Swimming, swarming and twitching were assessed using procedures
previously described (Manos et al., 2013). Brieﬂy, swimming, swarming
and twitching motilities were analysed using TSA plates with 0.3%,
0.5% and 1.5% (w/v) of agar, respectively, inoculated with 1× 108
CFU/mL of each colony morphotype-associated bacteria and incubated
for 24 h at 37 °C in air conditions. Swimming motility was assessed by
measuring the circular turbid zone around the inoculation point,
swarming by measuring the irregular branching that appeared at the
periphery of the colonies and twitching by measuring the hazy zone of
growth at the interface between the agar and the polystyrene surface.
2.8.3. Auxotrophy testing
This metabolic trait was investigated by determining the ability of
colony morphotypes-associated bacteria to grow on glucose M9
medium (AMESRO) with and without 0.2% (w/v) of casoamino acids
(Workentine et al., 2013). Colony morphotypes were transferred to M9
medium plates with and without casoamino acids and incubated at
37 °C and let grow for 24 and 48 h. Absence of growth on M9 media
without casoamino acids was indicative of auxotrophy.
2.8.4. Pigments production
Pigments production was inferred visually observing the colour of
colonies and the surrounding agar medium. Colonies exhibiting blue-
green, green, red and brown colours on TSA plates were considered
pyocyanin, pyoverdine, pyorubrin, pyomelanin producers (Mayer-
Hamblett et al., 2014a, b).
2.8.5. Hemolytic activity
The hemolytic activity of colony morphotypes-associated bacteria
was assessed using Columbia Agar (Lioﬁlchem) with 40% (v/v) of sheep
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blood (Probiologica) plates (CAB). Colony morphology-associated
bacteria were transferred to CAB plates and incubated 24 h at 37 °C in
air conditions. Hemolysin production was considered negative when no
clearing zones were observed around the colonies.
All the tests were performed at least 5 times and each test used 3
technical replicates to ensure precision of each method.
2.8.6. Antimicrobial susceptibility testing
The antimicrobial susceptibility proﬁle of each morphotype was
determined using the disk diﬀusion method for ten antibiotics com-
monly used to treat P. aeruginosa infections in CF context: amikacin
(AK) 30 μg, aztreonam (ATM) 30 μg, ciproﬂoxacin (CIP) 5 μg, to-
bramycin (TOB) 10 μg, gentamicin (CN) 10 μg, ceftazidime (CAZ) 30 μg,
cefepime (FEP) 30 μg, imipenem (IMI) 10 μg, piperacillin (PRL) 100 μg
and ticarcillin/clavulanic acid (TTC) 85 (75+ 10) μg, all obtained from
Lioﬁlchem. Disk diﬀusion susceptibility testing was performed in ac-
cordance with the recommendations of NCCLS document M100-522
(Clinical and Laboratory Standards Institute, 2012). The cartridges of
antibiotic disks were stored at -20 °C and allowed to come to room
temperature prior to use. The inhibition zones were measured (mm)
after 18–21 h at 37 °C in air conditions. Colony morphotypes-associated
bacteria were assigned as resistant (R), intermediate resistant (I) or
sensitive (S) as deﬁned by NCCLS guidelines in document M100-S28
(Clinical and Laboratory Standards Institute, 2018).
2.9. Statistical analysis
Continuous variables including CFU/mL and quantiﬁcation of bio-
ﬁlm biomass data (absorbance values) were the only variables analysed
statistically. CFU data retrieved from growth kinetics and time killing
curves were analysed by Mann–Whitney test, a non-parametric proce-
dure to assess a null hypothesis that two populations are the same. In
vitro ability to form bioﬁlms data (absorbance values) were analysed
using Kruskal Wallis (assumption of normality was not veriﬁed). All
statistical analyses were performed in SPSS version 20.0 (Chicago,
Illinois, USA) considering as level of statistical signiﬁcance p < 0.05.
3. Results
The main goal of this study was to inspect the possible early
adaptations that P. aeruginosa underwent after CF lungs colonization
using a long-term in vitro maintenance model mimicking CF lung en-
vironment. Our model was designed to allow the growth of P. aerugi-
nosa in ASM along 10 days in order to provide suﬃcient time to bac-
teria initiate their adaptation to CF environment. Through this in vitro
long-term growth in ASM, our study aimed to investigate: i) the oc-
currence of P. aeruginosa diversiﬁcation after simulated in vitro CF lungs
colonization and growth; ii) the driving forces underlying phenotypic
diversiﬁcation; iii) the impact of phenotypic diversiﬁcation on the ef-
fectiveness of the ﬁrst or early anti-pseudomonal treatments; and iv) the
P. aeruginosa response to ciproﬂoxacin long-term exposure. To gain
more valuable insights about the early adaptations that P. aeruginosa
can undergo, three diﬀerent strains were selected to simulate the main
sources and routes of P. aeruginosa transmission to CF patients. The
majority of CF patients are colonized by environmental strains (Burns
et al., 2001; Speert et al., 2002), which means these P. aeruginosa strains
never contacted with CF environment or human host. This scenario was
simulated using PAO1, a laboratory strain (Stover et al., 2000). During
CF patients visits to hospital or even during their hospitalizations, CF
patients can contact with other non- and CF individuals that can
transmit P. aeruginosa (UK Cystic Fibrosis Trust, 2004). To simulate
these two scenarios, two P. aeruginosa clinical isolates non- and CF re-
lated, PAI and ATCC, respectively, were chosen. The inclusion of the
ATCC strain also allowed to investigate whether a ﬁrst CF patient co-
lonization by a mucoid P. aeruginosa represents an increased risk to
develop a faster chronic infection, issue that stills controversial in
clinical community.
3.1. Growth kinetics of ASM-grown populations and time killing curves of
ciproﬂoxacin treatments
The growth kinetics of the three ASM-grown P. aeruginosa popula-
tions demonstrated identical growth proﬁles (Fig. 1). After one day of
exponential growth, the three ASM-grown populations achieved the
stationary phase with no diﬀerence in the number of viable cells among
all the populations. Regarding phenotypic diversity, results demon-
strated the occurrence of early diversiﬁcation, being the diversiﬁcation
proﬁles strongly strain-dependent (Fig. 2A). After 3 days of growth in
ASM, new colony morphotypes, diﬀerent from the ones observed in the
inoculum (day 0), emerged in P. aeruginosa PAI and ATCC populations
(Fig. 3 and S1). In contrast, ASM-grown PAO1 population did not ex-
hibit colony diversity.
P. aeruginosa PAI population exhibited the highest diversity since it
generated 4 new distinct morphotypes, all catalogued as SCV (MT04,
MT05, MT07 and MT10) (Table 1), but the new morphotypes had only
reached a maximum of 15% of estimated prevalence (Figure S1). In
turn, ATCC strain generated only one new morphotype, a dry variant
(MT12) more prevalent than WMT. Given these evidences of early
phenotypic diversiﬁcation, the mutation frequencies were determined
to inspect whether the existence of mutators could be the mechanism
underlying diversity. The expected absence of mutators in P. aeruginosa
populations at these early stages (data not shown) and the coexistence
of colony variants within the 10-day period of bacterial growth in ASM
pointed out that diversiﬁcation was not triggered by increased mutation
frequencies. Therefore, the results obtained until now led to speculate
that P. aeruginosa could phenotypically diversify after CF lungs colo-
nization and at early growth stages. Based on this evidence, it was
considered of vital clinical signiﬁcance to know whether this diversi-
ﬁcation could aﬀect antibiotic eﬀectiveness in P. aeruginosa early era-
dication from CF lungs. Accordingly, diﬀerent ciproﬂoxacin treatment
approaches were tested against non- and diversiﬁed P. aeruginosa po-
pulations grown in ASM varying antibiotic concentration. The inoculum
populations of the three strains used to colonize the ASM (day 0) did
not exhibit population diversity (Figs. 2 and 3). Therefore, one of the
ciproﬂoxacin treatment approaches started at day 0 to ensure that an-
tibiotic would act against non-diversiﬁed populations. The results ob-
tained from population diversity displayed in Fig. 2A were also crucial
to set down the timing of ciproﬂoxacin application against diversiﬁed
populations. As ASM-grown PAI and ATCC populations exhibited
colony morphology diversity after 3 days of growth, ciproﬂoxacin
treatments against diversiﬁed populations were initiated at day 5 of
bacterial growth to ensure well-established phenotypic diversity.
Fig. 1. Growth kinetics of ASM-grown P. aeruginosa strains over 10 days.
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Despite ASM-grown PAO1 population did not diversify its colony
morphology, this strain was included in these experiments to serve as
negative control of this mode of ciproﬂoxacin application. Beyond po-
pulation diversity, distinct ciproﬂoxacin concentrations (sub- and bio-
ﬁlm inhibitory) were used to evaluate the dosage-eﬀect on antibiotic
eﬀectiveness against non- and diversiﬁed P. aeruginosa populations.
According to Sriramulu et al. (2005), P. aeruginosa growth in ASM
promotes the formation of tight microcolonies attached to sputum
constituents or even could promote the formation of bioﬁlms. There-
fore, the antibiotic susceptibility proﬁles of ASM-grown P. aeruginosa
populations were expected to be similar to the bioﬁlm-cells. By this
reason, the ciproﬂoxacin concentrations were stipulated according to
the MIC of P. aeruginosa bioﬁlm-derived cells. All P. aeruginosa bioﬁlm-
cells exhibited identical MIC of 4mg/L of ciproﬂoxacin and, thus, 1 mg/
L (sub-inhibitory concentration equivalent of ¼ MIC) and 4mg/L
(inhibitory concentration) of ciproﬂoxacin were chosen to test anti-
biotic eﬃcacy against ASM-grown P. aeruginosa populations. Moreover,
the bacterial response to these distinct long-term antibiotic exposures
was also investigated.
The thorough analysis of the time killing curves (Fig. 4) highlighted
that the use of sub-inhibitory concentrations of 1mg/L of ciproﬂoxacin
against non-diversiﬁed populations was clearly ineﬃcient in the era-
dication of P. aeruginosa (Fig. 4A). This ciproﬂoxacin treatment ap-
proach seemed to have no signiﬁcant eﬀect over PAO1 population;
promote bacterial load reduction for the ATCC population, where a 3
log reduction was attained; and have no eﬀect against PAI population.
Ciproﬂoxacin eﬃcacy was improved using the inhibitory concentration
of 4mg/L (Fig. 4B) as ASM-grown PAO1 and ATCC populations were
eradicated after three days of treatment, even though no interference in
PAI growth was observed. Regarding antibiotic application over the
Fig. 2. Clonal diversiﬁcation of the ASM-grown P. aeruginosa over 10 days (A) without ciproﬂoxacin treatment, (B) in the presence of 1 and 4mg/L of ciproﬂoxacin
since day 0 (ciproﬂoxacin acting against non-diversiﬁed population), and (C) in the presence of 1 and 4mg/L of ciproﬂoxacin since day 5 (ciproﬂoxacin acting
against diversiﬁed population). Dash lines indicate when ciproﬂoxacin treatments were applied.
Fig. 3. Colony morphotypes isolated from ASM-grown P. aeruginosa populations over 10 days with and without ciproﬂoxacin treatment. All colonies were grown on
TSA for 48 h. Black bar= 1mm.
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phenotypically diversiﬁed populations, 1 mg/L of ciproﬂoxacin was
able to eradicate the diversiﬁed ATCC population, but did not aﬀect PAI
diversiﬁed population (Fig. 4C). Interestingly, a signiﬁcantly load re-
duction of the non-diversiﬁed ASM-grown PAO1 was obtained. The
outcomes related to the application of 1mg/L of ciproﬂoxacin at day 5
against diversiﬁed populations were not improved when ciproﬂoxacin
concentration was raised to 4mg/L (Fig. 4D). Improvements were only
noticed in the non-diversiﬁed PAO1 population that was eradicated. In
overall, the increase of ciproﬂoxacin dosage could be beneﬁcial for P.
aeruginosa eradication from ASM. However, this improvement of ci-
proﬂoxacin action did not seem to be related with the phenotypic di-
versiﬁcation of ASM-grown populations at this early stage of infection
development because both non- and diversiﬁed populations, PAO1 and
ATCC respectively, were eradicated using 1 and 4mg/L.
In what concerns ciproﬂoxacin action, determined by the number of
days needed to provoke bacterial eradication, its eﬃcacy was not
Table 1
Detailed morphological description of the colonies identiﬁed in ASM-grown P. aeruginosa populations with and without ciproﬂoxacin treatment.
Form Margin Sheath Type of Surface Texture Consistency Elevation Opacity Size Colour
PA01
WMT- MT02 circular undulate present homogeneous rough dry ﬂat opaque large yellow
MT17 circular undulate present homogeneous rough moist ﬂat opaque large yellow
ATCC
WMT - MT01 circular undulate present homogeneous smooth mucoid ﬂat opaque large beige
MT03 circular undulate present homogeneous rough dry ﬂat opaque large beige
MT12 circular undulate present homogeneous rough dry ﬂat transparent large beige
MT15 circular undulate present homogeneous rough dry ﬂat opaque pinpoint beige
MT19 circular undulate present homogeneous rough dry ﬂat opaque small beige
PAI
WMT - MT14 circular entire absent homogeneous rough dry ﬂat iridescent large Blue-green
MT04 circular undulate absent heterogeneous smooth/rough dry ﬂat iridescent small Blue-green
MT05 irregular undulate absent homogeneous wrinkled dry ﬂat iridescent small Blue-green
MT07 circular entire absent homogeneous rough dry ﬂat iridescent small Blue-green
PA01 and PAi
MT10ª circular entire absent homogeneous smooth mucoid ﬂat opaque small yellow
aMF10 was observed in both PA01 and PAI2 populations.
Fig. 4. Time killing curves of ciproﬂoxacin treatments. (A) Ciproﬂoxacin treatments using 1mg/L and (B) using 4mg/L over 10 days (applied at day 0) against non-
phenotypic diversiﬁed ASM-grown P. aeruginosa populations. (C) Ciproﬂoxacin treatments using 1mg/L and (D) using 4mg/L started at day 5 (indicated by the
arrow) over 5 days against ASM-grown phenotypic non- and diversiﬁed P. aeruginosa populations.
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impaired by the occurrence of phenotypic diversity of populations. An
increase in ciproﬂoxacin eﬃcacy was noticed when dosages of 1 and
4mg/L were applied against ATCC diversiﬁed population, as eradica-
tion was achieved in two days. However, ciproﬂoxacin eﬃcacy did not
change against non- and diversiﬁed PAI populations, where eradication
did not occur. These diﬀerent ciproﬂoxacin eﬃcacy results allowed to
verify that phenotypic diversiﬁcation of ASM populations did not im-
pair ciproﬂoxacin eﬃcacy at this early stage.
Altogether, our data evidenced that the eﬃcacy of the ﬁrst cipro-
ﬂoxacin treatments against early CF-adapted P. aeruginosa could be not
impaired by phenotypic diversiﬁcation, but it could be aﬀected by the
P. aeruginosa strain susceptibility. Indeed, WTM of PAO1 and ATCC,
MT02 and MT01 respectively, were susceptible to ciproﬂoxacin and
their ASM-grown populations were the most sensitive to ciproﬂoxacin
whatever the antibiotic treatment approach followed. On the other
hand, PAI was the most resistant strain, as no eradication or even
bacterial load reduction was achieved using all ciproﬂoxacin treat-
ments, and its WTM (MT14) was resistant to ciproﬂoxacin. Our results
also pointed out that ASM colonization by mucoid strains did not seem
to represent increased risk of accelerated infections development or
diminish antibiotic eradication as previously stated (Li et al., 2005;
Schelstraete et al., 2013).
3.2. P. aeruginosa populations response to ciproﬂoxacin treatments
Despite the still positive result of the antibiotic treatments over
early ASM-grown P. aeruginosa populations, ciproﬂoxacin seemed to
have the potential to trigger clonal diversiﬁcation into new colony
variants. When PAO1 populations were subjected to ciproﬂoxacin
treatment, new colony morphotypes emerged, including MT17 - a moist
variant - and MT10 – a mucoid SCV (Fig. 2B and C) that were not de-
tected in the non-treated PAO1 population (Fig. 2A). The same trend
was observed for ATCC populations with the emergence of MT03, MT15
(SCV) and MT19 (a pinpoint variant – diameter below 1mm). These
PAO1 and ATCC colony variants exhibited morphological features very
similar to those observed in clinical isolates from CF-associated chronic
infections, including mucoid-alike consistency (MT17) and small
(MT10 and MT15) and pinpoint size (MT19) (Table 1). Interestingly,
SCV and pinpoint variants from PAO1 and ATCC emerged with relevant
estimated prevalence within populations (Figure S1) that suﬀered a
bacterial load reduction caused by ciproﬂoxacin action.
The increase of ciproﬂoxacin dosage applied against non- and di-
versiﬁed ASM-grown populations did not seem increase the number of
morphotypes identiﬁed within populations. Population diversity only
increased from 4 to 5 morphotypes when the amount of ciproﬂoxacin
applied against PAI diversiﬁed populations at day 5 increased from 1 to
4mg/L.
The expected absence of mutators in ASM-grown P. aeruginosa PAO1
and ATCC populations exposed to ciproﬂoxacin treatments (data not
shown) led to propose that sub-inhibitory concentrations of cipro-
ﬂoxacin could be the driving forces underlying clonal diversiﬁcation
into possible “ﬁtter” variants. On the other hand, ciproﬂoxacin treat-
ments did not prompt clonal diversiﬁcation in ASM-grown PAI popu-
lations as no new colony morphotypes were observed (Fig. 2). WMT
and all SCV detected along ciproﬂoxacin treatments were identical to
those observed in the non-treated ASM-grown PAI population. The
tolerance of WMT and all SCV to ciproﬂoxacin (Table 2) may sub-
stantiate that there is no need of this bacterial population in diversify
into new variants to counteract antibiotic stress.
3.3. Pathogenic potential of the colony morphology-associated bacteria
Data derived from our study highlighted that early phenotypic di-
versity of ASM-grown P. aeruginosa populations did not seem to inter-
fere with ciproﬂoxacin eﬃcacy (Fig. 4), not corroborating previous
ﬁndings that a diverse population has more chances to persist under
stressful conditions, as antibiotic treatments (Boles et al., 2004; Boles
and Singh, 2008; Ashish et al., 2013). To better understand these out-
comes, the pathogenic potential of all colony variants-associated bac-
teria isolated from the ASM-grown P. aeruginosa populations, diﬀerent
from WMT, was investigated including the antibiotic susceptibility and
the most relevant virulence factors expression in CF context. Our results
revealed that the colony morphotype-associated bacteria expressed
diﬀerent combinatorial virulence determinants and antibiotic suscept-
ibility proﬁles, suggesting some biological ﬁtness of P. aeruginosa po-
pulations that harbour distinct colony variants. The colony variants-
associated bacteria of P. aeruginosa exhibited variable ability to form
bioﬁlms (Fig. 5A) and pigment production (pyocyanin and pyomelanin)
and no alteration in hemolysin, pyoverdine and pyorubrin production,
auxotrophy (Table 3) and swarming and twitching motility (Fig. 5C and
D). We must highlight the particular increased ability of PAI morpho-
types to form bioﬁlms with impressive amount of biomass (Fig. 5A),
which may explain the ineﬃcacy of ciproﬂoxacin over PAI populations.
Among the variability of virulence factors expression, the emergent
colony morphotype-associated bacteria exhibited impaired swimming
motility in contrast to WMT (Fig. 5B). These results seem to indicate
that P. aeruginosa evolved to a non-swimming phenotype and this ob-
servable characteristic may be an indicator of P. aeruginosa adaptation
to CF environment and of the onset of infection development. However,
to unambiguously establish this feature as a hallmark of CF early in-
fections, more P. aeruginosa strains need to be studied, as well as using
in vitro models mimicking as much as possible the heterogeneous
characteristics of the inﬂamed and polymicrobially colonized CF lungs.
Regarding antibiotic susceptibility, the majority of the new colony
variants-associated bacteria exhibited antibiotic resistance to cipro-
ﬂoxacin either by heritance, such as PAI morphotypes, or by exposure
to ciproﬂoxacin, such as MT10 and MT15 (Table 2). The exposure to
ciproﬂoxacin might also contribute to the emergence of colony var-
iants-associated bacteria with augmented resistance against no-related
antibiotics including ticarcillin, as evidenced by MT17, and imipenem,
exhibited by MT15 and MT19.
In overall, the emergent colony variants-associated bacteria still
preserve several WMT features, but our results pointed out that im-
portant pathogenic traits for infection development were altered, such
as resistance to antibiotics and impaired swimming motility.
Table 2
Antibiotic susceptibility of the colony morphotypes-associated bacteria de-
tected in ASM-grown P. aeruginosa populations.
Antibiotic susceptibility
CIP CN TOB AK IMI ATM CAZ FEP TTC PRL
PA01
MT02 (WMT) S S S S S S S S S S
MT17 S S S S S S S S I S
MT10 I S S S S S S S S S
ATCC
MT01 (WMT) S S S S S S S S S S
MT12 S S S S S S S S S S
MT03 S S S S S S S S S S
MT19 S S S S I S S S S S
MT15 R S S S I S S S S S
PAI
MT14 (WMT) R S S S S I S S I S
MT04 R S S S S S S S S S
MT05 R S S S S I S S I S
MT07 R S S S S I S S I S
MT10 I S S S S S S S S S
S – susceptible; I – intermediate resistant; R – resistant.
CIP – ciproﬂoxacin; CN – gentamicin; TOB – tobramycin; AK- amikacin; IMI
imipenem; ATM – aztreonam; CAZ – ceftazidime; FEP – cefepime; TTC - ti-
carcillin/clavulanic acid ; PRL – piperacillin.
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4. Discussion
Understanding P. aeruginosa evolution and diversiﬁcation along the
course of infections in CF lungs is of upmost importance, mainly for the
decision of the antibiotic treatments to be administered to patients.
Nevertheless, those evolutionary processes at the early stage of infec-
tion are poorly characterized, remaining unknown what happens im-
mediately after P. aeruginosa lungs colonization. The less amount of
information concerning early infection stages is mainly due to the need
of continuous sampling of the patient sputum until detection of P.
aeruginosa colonization. The diﬃculty of determining with precision
this onset of colonization limits the ability to deﬁne when P. aeruginosa
starts its adaptation and, thus, the scrutiny of which are the new
emergent CF-adapted phenotypes and what are the driving forces of
that diversiﬁcation. Therefore, in vitro studies have a crucial role to
provide valuable insights into what occurs to P. aeruginosa after enter in
CF lungs.
Clonal diversiﬁcation has been reported as a source of phenotypic
Fig. 5. Virulence factors expression by the colony morphotype-associated bacteria. (A) Ability to form bioﬁlms; B) swimming motility; C) swarming motility; D)
twitching motility. Note: As no statistically signiﬁcant diﬀerences were found in swimming, swarming and twitching motility among the WMT of the three P.
aeruginosa strains and among the several new colony morphotypes, the error bars were omitted to facilitate the results reading.
Table 3
Virulence factors expression exhibited by emergent colony morphotypes-associated bacteria detected in ASM-grown P. aeruginosa populations in comparison to WMT.
Virulence factors expression
Hemolysin Auxotrophy Pyoverdine Pyocyanin Pyomelanin Pyorubrin
PA01
MT02 (WMT) +* – – – – –
MT17 +* – – – – –
MT10 – – – – – –
ATCC
MT01 (WMT) – – – – + –
MT12 – – – ++ – –
MT03 – – – – – –
MT19 – – – – – –
MT15 – – – – – –
PAI
MT14 (WMT) – – – ++ – –
MT04 – – – + + –
MT05 – – – + + –
MT07 – – – + + –
MT10 – – – – + –
*slight hemolysin activity.
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heterogeneity with a role in bacterial adaptation to new environments
(Rakhimova et al., 2009; Klockgether et al., 2013; Browall et al., 2014;
Markussen et al., 2014). In CF disease, it is well-known that clonal di-
versiﬁcation has a fundamental role in chronic infection development
and persistence (Klockgether et al., 2013; Markussen et al., 2014; Sousa
and Pereira, 2014). In contrast, it is unclear whether clonal diversiﬁ-
cation can also occur after CF lungs colonization and if it helps the
development of early infections. Moreover, it is unknown whether the
occurrence of early phenotypic diversiﬁcation could be the cause of the
failure of the ﬁrst anti-pseudomonal antibiotic treatments and pave the
way for the faster development of chronic infections. To clarify these
issues, our study aimed to analyse the early adaptation events of three
distinct P. aeruginosa populations after simulating in vitro ﬁrst coloni-
zation of CF lungs.
The in vitro model used in our study was constructed based on the
ASM model described by Sriramulu et al. (2005). ASM provides quite
similar chemical and nutritional conditions to those found in CF lungs,
however in the scope of our study the use of ASM was not considered
enough when a complex evolutionary pathway of this pathogenic agent
is being investigated. P. aeruginosa evolutionary pathway in CF lungs
towards chronic infections frequently takes several months or even
years. Therefore, it is important to let bacteria grow in ASM as long as
the in vitro conditions would permit in order to bacteria trigger the
mechanisms that this bacterium would use in in vivo scenario. So, in our
study, P. aeruginosa was allowed to grow in ASM over 10 days to pro-
vide time to bacteria initiate their adaptation to this new environment.
Using this experimental setup, each evolutionary step of P. aeruginosa
after ASM colonization and at early stage of infection could be mon-
itored.
Our study provided evidences that ASM-grown P. aeruginosa popu-
lations evolved along time generating diverse sub-populations strain-
dependent, noticeable by the distinct colony morphotypes. So, we
speculated that clonal diversiﬁcation could start occurring immediately
after CF lungs colonization. Nevertheless, WMT of PAO1 strain did not
diversify after in vitro simulated CF lungs colonization and along 10
days. This evidence led us to consider that WMT PAO1 was prepared to
grow in ASM with no need to generate “ﬁtter” variants. In this situation,
we hypothesized that diversiﬁcation might occur triggered by altera-
tions in CF environment, such as antibiotic treatments.
Each P. aeruginosa ASM-grown population was composed by distinct
colony morphotypes despite all strains belong to the same bacterial
species. This intra-strain diversity may be explained by the diﬀerent
function of the central elements in genome, despite the genes involved
in regulation were highly conserved. This instability of the core ele-
ments of regulation is suﬃcient to generate distinct clonal diversiﬁca-
tion and adaptive pathways among strains (Ryall et al., 2012).
The presence of mutators within populations can accelerate P. aer-
uginosa CF-adaptation through high mutation rates up to 1000–fold
than non-mutator phenotypes (Oliver et al., 2000; Mena et al., 2008;
Rodriguez-Rojas et al., 2012). Despite mutators are known to be not
eﬃcient to establish a primary infection (Montanari et al., 2007), their
presence in the ASM-grown P. aeruginosa populations was investigated
to unequivocally discard them as a cause of diversity. As expected,
mutators were not detected that led to speculate that the driving forces
for the observed diversiﬁcation might be related with niche speciali-
zation. Markussen et al. (2014) also found initial infecting strain di-
versiﬁcation into distinct sublineages immediately after initial lungs
colonization and proposed niche partitioning as the driving force for
phenotypic diversiﬁcation. CF sputum is known to be intrinsically
heterogeneous and highly structured environment with multiple com-
partments where distinct environmental conditions could be found, for
instance, diﬀerent oxygen and nutrient availability, antibiotic mole-
cules and immune cells (Worlitzsch et al., 2002; Hoﬀman et al., 2010).
Bacteria ﬁll in these distinct ecological compartments leading to niche
specialization and, consequently, to population diversity. ASM in the
24-well plates had a depth of approx. 1.4 cm that incubating statically
along 10 days might has allowed to mimic diﬀerent oxygen diﬀusion
and provoking diﬀerent availability. Moreover, during our experiments
several visible aggregates within ASM suspensions with distinct size and
apparent density were observed that could be indicative of aggregated
or bioﬁlm formation. These possible distinct bacterial lifestyles (free
living and bioﬁlm) could result in diﬀerent access to nutrients. So, these
observations led us to hypothesize that ASM could also mimic niche
specialization of CF sputum. The rapid diversiﬁcation of P. aeruginosa
after initial ASM colonization in our study could be caused by the ex-
istence of several niches within ASM determined by the diﬀerent
oxygen and/or nutrient concentrations in which bacteria grow leading
to several sub-populations. The topic of niche specialization within CF
sputum is very diﬃcult to unravel due to the lack of both in vitro and in
vivo studies. The results of our study reinforced that more eﬀorts must
be addressed to clarify the role of niche specialization since early stages
of infection.
According the ‘Insurance Hypothesis’, (more) diversity within a
population enhances its functioning against a wide range of adverse
environmental ﬂuctuations increasing thus the chances of survival [43].
Therefore, we hypothesized that early phenotypic diversiﬁcation could
be the cause of the failure of the ﬁrst anti-pseudomonal treatments in P.
aeruginosa eradication from CF lungs. Our results demonstrated that
early phenotypic diversiﬁcation of P. aeruginosa did not represent a
critical issue for antibiotic treatments, at least, at early infection stage.
The eﬃcacy of ciproﬂoxacin to eradicate ASM-grown populations
seemed to be more aﬀected by P. aeruginosa antibiotic susceptibility
than by population diversity. ASM-grown PAI populations resisted to all
ciproﬂoxacin treatments probably due to WMT resistance to cipro-
ﬂoxacin, in contrast to PAO1 and ATCC ASM-populations that were
susceptible to ciproﬂoxacin similarly to their WMT. PAO1 strain has no
gene islands encoding relevant virulence factors to tolerate aggressive
concentrations of antibiotic which might explained its facilitated era-
dication (Stover et al., 2000). Early colonization of the CF airways with
mucoid strains is often associated with an accelerated rate of decline in
pulmonary function (Li et al., 2005; Schelstraete et al., 2013). Ac-
cording our results, the mucoidy feature of the ATCC strain did not
appear to confer any additional biological advantage to P. aeruginosa to
adapt to CF environment or protection against the antimicrobial ac-
tivity of ciproﬂoxacin. Mayer-Hamblett et al. (2014a,b) did not ﬁnd as
well an association of mucoidy with severe infection development. In
contrast, ﬁrst P. aeruginosa acquisition from non-CF individual seemed
to represent a risk factor because PAI populations were not eradicated.
These assumptions should be tested with other non- and mucoid strains.
Although phenotypic diversity did not have impact on ciproﬂoxacin
eﬃcacy, antibiotic concentration revealed to be important in early
eradication of P. aeruginosa. Beyond sub-bioﬁlm inhibitory concentra-
tions of ciproﬂoxacin did not demonstrate to be eﬀective in P. aerugi-
nosa eradication, they seemed to promote clonal diversiﬁcation into
new variants. The new emergent colony variants exhibited some typical
traits of chronic isolates (Sousa and Pereira, 2014), such as small size,
the SCV, (MT10, MT15 and MT19) and mucoid consistency (MT10) or
mucoid-trend consistency (MT17). Moreover, these variants exhibited
some altered antibiotic susceptibility to ciproﬂoxacin and to non-re-
lated antibiotics. Other studies also found that sub-inhibitory con-
centrations of antibiotic can drive diversiﬁcation and selection of po-
pulations with distinct antibiotic resistance levels in response to
diﬀerent ciproﬂoxacin concentrations (Macia et al., 2006; Wright et al.,
2013).
The expected absence of mutators within ASM-grown populations
under sub-inhibitory ciproﬂoxacin treatments supported the assump-
tion that sub-inhibitory dosages might function as driving forces for
clonal diversiﬁcation into “ﬁtter” variants. Indeed, sub-inhibitory or
sub-lethal concentrations of antibiotics can act as signalling molecules
regulating gene transcription, physiology and virulence potential (Shen
et al., 2008; Skindersoe et al., 2008; Cummins et al., 2009; Douglas
et al., 2009) inducing mutations and recombinations and, consequently,
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supporting the emergence of phenotypic variants (Kohanski et al.,
2010; Rodriguez-Rojas et al., 2012; Wright et al., 2013). The emergence
of colony morphotypes with mucoid consistency (MT10), small (MT10
and MT15) and pinpoint size (MT19) under antibiotic pressure at early
stage could be understood as an attempt of P. aeruginosa to adapt to the
harmful conditions imposed. We hypothesized that these new-arise
colony variants started to exhibit some phenotypic characteristics dis-
tinct from those displayed by WMT to escape the toxic action of ci-
proﬂoxacin, augmenting thus their bacterial pathogenicity.
The long-term in vitromaintenance of P. aeruginosa in ASM provided
a valuable opportunity to detect one of its ﬁrst steps of the evolutionary
pathway in CF lungs. Although colony morphotypes-associated bacteria
still preserve several WMT characteristics, the ﬁrst steps of micro-
evolution and adaptation were noticed through the increased ability to
form bioﬁlms that some colony morphotypes demonstrated, but, more
importantly, the evident impaired swimming motility that the majority
of them exhibited. Swimming motility is promoted by ﬂagella and their
lack inhibit swimming movement facilitating other further phenotypic
adaptations, such as aggregation (bioﬁlm formation) that confer pro-
tection against to antibiotics and host immune molecules
(Mahenthiralingam et al., 1994; Staudinger et al., 2014). Mayer-
Hamblett et al. (2014a,b) found an association between defective
swimming ability and pulmonary exacerbations, worsening symptoms
and declining lung function, the common signs of infection develop-
ment (Bilton et al., 2011; Mowat et al., 2011; Stressmann et al., 2011).
Therefore, we hypothesized the emergence of colony variants-asso-
ciated bacteria with impaired swimming motility detected in our study
may be at the root of the ﬁrst P. aeruginosa infections and the beginning
of lung function decline in CF patients. Several other studies have de-
scribed defective swimming ability as a characteristic of CF chronic
isolates (Mahenthiralingam et al., 1994; Manos et al., 2013; Staudinger
et al., 2014) which reinforce our assumption that impaired swimming
motility could be considered one of the early adaptationsof P. aerugi-
nosa towards infection development. Defective swimming motility
could be a potential disease marker with great impact on clinical di-
agnosis. As swimming measures can be performed in a reproducible and
quantitative way, an easily diagnosis of early P. aeruginosa adaptation
could be achieved. Therefore, it is urgent that more studies address the
early adaptive events that P. aeruginosa undergoes in CF lungs to
strengthen this suggestion of early adaptation marker.
Our long-term in vitro maintenance model represent a step forward
towards in vivo scenario and it provided valuable insights about the
early evolutionary steps of P. aeruginosa in CF environment. However, it
did not fully mimic the complex environment of CF lungs. Therefore,
more studies using improved in vitro models, mimicking as much as
possible the heterogeneous characteristics of CF lungs, and encom-
passing more P. aeruginosa strains, mono- or co-cultured with other
bacteria, need to be carried out to unequivocally establish early clonal
diversiﬁcation occurrence and impaired swimming motility as the
stamp of the early onset P aeruginosa infection in CF patients.
5. Conclusions
Our results evidenced that clonal diversiﬁcation typically detected
in chronic infection stages, could begin immediately after CF lungs
colonization by P. aeruginosa in a strain-dependent way. We hypothe-
sized that this diversiﬁcation could be driven by niche specialization in
which bacteria organize themselves spatially into distinct ecological
niches of CF sputum. However, at this early stage of infection, clonal
diversiﬁcation did not have signiﬁcant impact on ciproﬂoxacin eﬀec-
tiveness since bioﬁlm inhibitory dosages would be applied. The use of
bioﬁlm sub-inhibitory concentrations, besides not be eﬀective in P.
aeruginosa eradication, can trigger the emergence of colony variants
exhibiting characteristics very alike to chronic isolates, including SCV,
pinpoint and mucoid variants resistant to antibiotics. Our evidences are
of vital clinical signiﬁcance because they highlighted that inadequate
ﬁrst antibiotic dosages, beyond do not treat infection, may select re-
sistant bacteria, contributing to infection resilience to subsequent an-
timicrobial interventions. The analysis of the pathogenic potential of all
emergent colony variants-associated bacteria, isolated from the several
ASM experiments, revealed that, comparing to WMT, P. aeruginosa
evolve to a non-swimming phenotype. These ﬁndings led us to suggest
that impaired swimming motility could be the hallmark of the onset of
early infection and one of the very ﬁrst steps of the long and complex
evolutionary pathway towards chronic infections. Thus, limited swim-
ming motility could be a potential candidate for CF early infection
biomarker, hypothesis that needs to be tested by analysing the pheno-
typic and pathogenic behaviour of more P. aeruginosa isolates.
The outcomes of our study will certainly assist the accurate design
of the ﬁrst anti-pseudomonal antimicrobial treatments and increase
their successful eradication rates. Despite the usefulness of the in vitro
long-term growth of P. aeruginosa used in this study, this in vitro model
has only allowed the detection of some of the ﬁrst evolutionary steps
that are at the root of the long and complex pathway towards chronic
infection. CF lungs are extremely complex environment and other
characteristics such as excessive inﬂammation response and their
polymicrobial nature should be simulated in the in vitro studies to ob-
tain results closer to the in vivo onset of infection. Only by this way we
will able to understand the early P. aeruginosa adaptation to CF lungs
and the events underlying the transition of early infection to chronic
infection.
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